Stocktoria
Arcturus Therapeutics Holdings Inc. ARCT
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2013-05-22
Arcturus Therapeutics Holdings Inc. financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M | $9.5M | $20.8M | $15.8M |
| R&D expense | $112.2M | $195.2M | $192.1M | $147.8M | $173.8M | $57.8M | $33.6M | $17.0M |
| Operating income | -$76.3M | -$95.7M | -$78.2M | $12.2M | -$202.9M | -$71.5M | -$25.5M | -$21.8M |
| Income tax | — | -$4,000 | $1.8M | $1.3M | — | — | — | — |
| Net income | -$65.8M | -$80.9M | -$29.7M | $9.3M | -$203.7M | -$72.1M | -$26.0M | -$21.8M |
| EPS (diluted) | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 | — | — | — |
| Operating cash flow | -$74.3M | -$59.7M | -$18.1M | $32.0M | -$135.0M | -$42.9M | -$6.4M | -$20.8M |
| Free cash flow | -$74.5M | -$60.4M | -$21.0M | $24.3M | -$138.4M | -$44.6M | -$7.3M | -$22.2M |
| Cash & equivalents | $230.9M | $237.0M | $292.0M | $391.9M | $370.5M | $462.9M | $71.4M | $36.7M |
| Total assets | $271.1M | $344.1M | $429.4M | $450.4M | $392.8M | $476.5M | $82.1M | $44.2M |
| Total liabilities | $57.2M | $103.1M | $150.9M | $180.1M | $164.6M | $79.9M | $56.4M | $30.6M |
| Shareholders' equity | $214.0M | $241.0M | $278.5M | $270.3M | $228.2M | $396.6M | $25.8M | $13.6M |
Growth · year-over-year · Revenue CAGR 26.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -46.1% | -8.7% | -19.0% | +1566.8% | +29.6% | -54.1% | +32.0% | — |
| Net income growth | — | — | -417.9% | — | — | — | — | — |
| EPS growth | — | — | -420.0% | — | — | — | — | — |
| Free cash flow growth | — | — | -186.5% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.